ADVM Stock Overview
A clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Adverum Biotechnologies, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.86 |
52 Week High | US$29.70 |
52 Week Low | US$6.38 |
Beta | 1.13 |
11 Month Change | -14.46% |
3 Month Change | -51.49% |
1 Year Change | -56.86% |
33 Year Change | -80.68% |
5 Year Change | -94.36% |
Change since IPO | -97.27% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Feb 24We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
Sep 07Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10
Aug 11Adverum gains 13% to reach three-month high after Truist upgrade
Jul 07We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
May 12We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Jul 17Adverum Biotechnologies: An Uncertain Path Forward
May 05Adverum Bio presents long-term data from ADVM-022 trial in wet AMD
May 03We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Apr 06Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
Feb 13Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy
Feb 02Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares
Jan 22Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market
Jan 11Adverum Biotechnologies announces new GMP gene therapy manufacturing facility
Jan 07How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?
Dec 31Adverum ticks lower on underwhelming data from gene therapy in wet-AMD
Nov 16Shareholder Returns
ADVM | US Biotechs | US Market | |
---|---|---|---|
7D | 1.9% | -0.7% | 0.04% |
1Y | -56.9% | 10.0% | 20.7% |
Return vs Industry: ADVM underperformed the US Biotechs industry which returned 11% over the past year.
Return vs Market: ADVM underperformed the US Market which returned 22.5% over the past year.
Price Volatility
ADVM volatility | |
---|---|
ADVM Average Weekly Movement | 7.0% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ADVM's share price has been volatile over the past 3 months.
Volatility Over Time: ADVM's weekly volatility has decreased from 14% to 7% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 121 | Laurent Fischer | adverum.com |
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.
Adverum Biotechnologies, Inc. Fundamentals Summary
ADVM fundamental statistics | |
---|---|
Market cap | US$144.88m |
Earnings (TTM) | -US$112.90m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs ADVM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ADVM income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$72.03m |
Gross Profit | -US$72.03m |
Other Expenses | US$40.87m |
Earnings | -US$112.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -5.44 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ADVM perform over the long term?
See historical performance and comparison